The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07157852
- Record updated
- 25 June 2026
- Original description
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.Read full original descriptionShow less
Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Mirogabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or mirogabalin in treating FM, with the aim of providing a better treatment option for FM patients.
Inclusion: Newly diagnosed with FM according to the 2016 Revisions to the 2010/2011 FM diagnostic criteria;[1]; Aged over 18 years old; Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM; Baseline numeric rating scale (NRS) score of 4 or higher; Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range; Estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m²; Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements.
Exclusion: Previous allergic reactions to pregabalin, mirogabalin, or any of their excipients; Prior diagnosis of epilepsy or depression requiring antidepressant therapy; Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment; Suffering from acute or chronic pain disorders other than FM; Women who are pregnant or breastfeeding.